205640-31-9

Basic information

• Product Name: 2-((3-(((benzyloxy)carbonyl)amino)propanoyl)oxy)acetic acid
• Synonyms: 2-((3-(((benzyloxy)carbonyl)amino)propanoyl)oxy)acetic acid
• CAS NO: 205640-31-9
• Molecular Weight: 281.265
• Mol File: 205640-31-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-((3-(((benzyloxy)carbonyl)amino)propanoyl)oxy)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-((3-(((benzyloxy)carbonyl)amino)propanoyl)oxy)acetic acid(205640-31-9)
• EPA Substance Registry System: 2-((3-(((benzyloxy)carbonyl)amino)propanoyl)oxy)acetic acid(205640-31-9)

Safety Data

• Hazardous Substances Data: 205640-31-9(Hazardous Substances Data)

Upstream product

• 2304-94-1 3-(benzyloxycarbonylamino)propanoic acid 

Downstream Products

• 1308398-71-1 cabazitaxel Cbz-β-alanine glycolate 
• 1308398-73-3 cabazitaxel β-alanine glycolate methanesulfonate 
• 1308398-58-4 larotaxel β-alanine glycolate 
• 1246449-83-1 docetaxel-2'-β-alanine glycolate methanesulfonate 
• 1308398-56-2 larotaxel Cbz-β-alanine glycolate 
• 1246449-81-9 (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((R)-12-((S)-((tert-butoxycarbonyl)amino)(phenyl)methyl)-3,7,10-trioxo-1-phenyl-2,8,11-trioxa-4-azatridecan-13-oyl)oxy)-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate 

Relevant articles and documents

Discovery of a Novel Cabazitaxel Nanoparticle-Drug Conjugate (CRLX522) with Improved Pharmacokinetic Properties and Anticancer Effects Using a β-Cyclodextrin-PEG Copolymer Based Delivery Platform

Novel nanoparticle-drug conjugates (NDCs) containing diverse, clinically relevant anticancer drug payloads (docetaxel, cabazitaxel, and gemcitabine) were successfully generated and tested in drug discovery studies. The NDCs utilized structurally varied linkers that attached the drug payloads to a β-cyclodextrin-PEG copolymer to form self-assembled nanoparticles. In vitro release studies revealed a diversity of release rates driven by linker structure-activity relationships (SARs). Improved in vivo pharmacokinetics (PK) for the cabazitaxel (CBTX) NDCs with glycinate-containing (1c) and hexanoate-containing linkers (2c) were demonstrated, along with high and sustained tumor levels (>168 h of released drug in tumor tissues). This led to potent efficacy and survival in both taxane- and docetaxel-resistant in vivo anticancer mouse efficacy models. Overall, the CBTX-hexanoate NDC 2c (CRLX522), demonstrated optimal and improved in vivo PK (plasma and tumor) and efficacy profile versus those of the parent drug, and the results support the potential therapeutic use of CRLX522 as a new anticancer agent.

METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS

Described herein are methods for treating a subject with combinations of polymer-agent particles and cyclodextrin polymer agent conjugates. The methods herein may be used to treat subjects identified with cancer, cardiovascular disorders, autoimmune disorders, or inflammatory disorders. Also described herein are compositions, dosage forms, and kits comprising polymer-agent particles and cyclodextrin polymer agent conjugates.

Synthesis of taxoids II. Synthesis and antitumor activity of water-soluble taxoids

Synthesis of novel taxoid water-soluble prodrugs that have 2′-substituted amino acid derivatives with spacer is described. Enantioselective synthesis of the C-13 side chains proceeded through the asymmetric dihydroxylation. Several compounds had good solubility in saline and showed potent antitumor activity against B16 melanoma in mice.